secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0000950170-25-072825
Event type: earnings
Sentiment:  negative
Materiality: 0.82
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Q1 net loss $2.2M; closed $5M equity offering; going concern doubt
--------------------------------------------------------------------------------

- Q1 revenue $5,065 vs $1.1M prior year; net loss $2.2M vs $7.5M prior; R&D down 30% to $1.5M; G&A up 42% to $2.2M.
- Closed $5.0M equity offering on May 15 with one institutional investor; used to fund Phase 1 trial for HCW9302 in alopecia areata.
- Delivered technology report to WY Biotech for licensing of HCW11-006; expects $7.0M upfront fee after 30-day diligence.
- Received Nasdaq compliance letter for bid price, public float, MVPHS; must comply with all listing rules by June 16, 2025.
- Substantial doubt about ability to continue as going concern for 12 months; additional funding needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025072825/0000950170-25-072825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017025072825/hcwb-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-072825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer